Regeneron Pharma Q4 Results Top Estimates - Update
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
Excluding items, adjusted earnings for the quarter $1.37 billion or $11.86 per share, compared to $1.45 billion or $12.56 per share in the year-ago quarter.
On average, 21 analysts polled by Thomson Reuters expected the company to report earnings of $10.87 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the quarter edged up 1 percent to $3.43 billion from $3.41 billion in the same quarter last year. Excluding Ronapreve, revenue grew 14 percent. Analysts were looking for revenues of $3.29 billion for the quarter.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Regeneron Pharma Q2 Results Top Estimates - Update
Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
NZ Dollar Slides Against Majors
Australian Dollar Falls Against Majors
European Shares Poised For Weak Start As Fed Rate Cut Hopes Fade
